Research
Hormonal
Probiotic and synbiotic supplementation improves glycemic control, lipid profiles, and reduces inflammation in patients with type 2 diabetes and obesity, with strain-specific effects.
Taking specific probiotic or synbiotic supplements daily can modestly improve blood sugar and cholesterol levels in people with diabetes or obesity. Choose strains with clinical evidence (like Lactobacillus acidophilus or Bifidobacterium lactis) and take them consistently for at least 12 weeks.
GoodSupportsHIGH confidence
Meta-analyses found that probiotics improved fasting blood glucose levels and hemoglobin A1c (HbA1c) in patients with type 2 diabetes, and reduced body mass index and body weight in obese individuals.
Why this rating
Supported by multiple meta-analyses of RCTs with large pooled samples.
Source
Harnessing Microbiome Therapy to Treat Metabolic Syndrome
Mustafa Al Jnainati et al. · AACE Endocrinology and Diabetes · 2026
DOI 10.1016/j.aed.2025.11.015
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle interventions (diet and exercise) remain the most cost-effective and durable strategy for weight loss and diabetes prevention, outperforming microbiome therapies in long-term weight management.Strong
- Fecal microbiota transplantation (FMT) from lean donors transiently improves insulin sensitivity and glucose metabolism in patients with metabolic syndrome, though effects often diminish after 18 weeks without maintenance.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →